Epcot

Epcot is a French biotechnology company focused on developing next-generation inhibitors of the DNA Damage Response (DDR) pathway to treat various forms of cancer. The company leverages its proprietary platform to design highly selective small molecules targeting key enzymes such as DNA-PK, ATM, and ATR, which are critical for repairing DNA double-strand breaks in tumor cells. By inhibiting these repair mechanisms, Epcot aims to enhance the efficacy of traditional radiotherapy and chemotherapy, as well as provide monotherapy options for tumors with specific genetic vulnerabilities. Currently in the pre-clinical stage, the company is advancing a pipeline of candidates designed to overcome the limitations of first-generation DDR inhibitors, particularly regarding blood-brain barrier penetration and systemic toxicity.